Portopulmonary hypertension and the issue of survival

Liver Transplantation

Volumn 11, Issue 9, 2005, Pages 1026-1027

  Krowka, Michael J ^a,b  

^a Mayo Clinic   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

COMORBIDITY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; HEART FUNCTION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCORING SYSTEM; SHOCK; SURVIVAL RATE; SURVIVAL TIME;

HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER FAILURE; LIVER TRANSPLANTATION; SURVIVAL;

EID: 25144523526     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20494     Document Type: Editorial

References (15)

1. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chickpo CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111.
2. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: Analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-498.
3. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
4. Swanson KL, Wiesner RH, Krowka MJ. Survival in portopulmonary hypertension and orthotopic liver transplantation (abstract). Liver Transpl 2005;11:c71.
5. Krowka MJ, Frantz RF, McGoon MD, Wiesner RH. Improvement if pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
6. Minder S, Fischier M, Muelhaupt B, Zalunardo MO, Jenni R, Clavien PA, Speich R. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004;24:703-707.
7. Halank M, Marx C, Miehlke S, Hoeftken G. Use of inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004;39:1222-1223.
8. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004;77:1775-1776.
9. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy? Gastroenterology 2005;128:164-168.
10. Hoeper MM, Halank M, Hoeffken G, Seyfarth HJ, Schauer J, Niedermer J, et al. Bosentan for the treatment of portopulmonary hypertension. Eur Respir J 2005;25:502-508.
11. Clift PF, Bramhall S, Isaac JL. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004;77:1774-1776.
12. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945-950.
13. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005;24:498-500.
14. Krowka MJ, Plevak DJ, Findlay JF, Rosen CB, Wiesner RH, Krom RAF. Pulmonary hemodynamics and perioperative cardiopulmonary related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
15. Krowka MJ, SM Mandell, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database. Liver Transpl 2004;10:174-182.